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Abstract
Background: Severe malaria is a major contributor of deaths in African children up to five years of age. One
valuable tool to support health workers in the management of diseases is clinical practice guidelines (CPGs)
developed using robust methods. A critical assessment of the World Health Organization (WHO) and Kenyan
paediatric malaria treatment guidelines with quinine was undertaken, with a focus on the quality of the evidence
and transparency of the shift from evidence to recommendations.
Methods: Systematic reviews of the literature were conducted using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) tool to appraise included studies. The findings were used to
evaluate the WHO and Kenyan recommendations for the management of severe childhood malaria.
Results: The WHO 2010 malaria guidance on severe malaria in children, which informed the Kenyan guidelines,
only evaluated the evidence on one topic on paediatric care using the GRADE tool. Using the GRADE tool, this
work explicitly demonstrated that despite the established use of quinine in the management of paediatric cases of
severe malaria for decades, low or very low quality evidence of important outcomes, but not critical outcomes
such as mortality, have informed national and international guidance on the paediatric quinine dosing, route of
administration and adverse effects.
Conclusions: Despite the foreseeable shift to artesunate as the primary drug for treatment of severe childhood
malaria, the findings reported here reflect that the particulars of quinine therapeutics for the management of
severe malaria in African children have historically been a neglected research priority. This work supports the
application of the GRADE tool to make transparent recommendations and to inform advocacy efforts for a greater
research focus in priority areas in paediatric care in Africa and other low-income settings.
Background
Severe falciparum malaria is a medical emergency. An
estimated 800,000 annual deaths occur in African coun-
tries South of the Sahara as a direct result of malaria in
children aged five years and less [1]. The Roll Back Malaria
Partnership’s goal is to control and ultimately eliminate
malaria, which is consistent with the Millennium Develop-
ment Goals (MDGs) 4, to reduce under-five child mortal-
ity, and 6 to reduce the incidence of infectious diseases
including malaria. However, until achieved, appropriate
treatment of severe malaria to prevent fatality and
disability will be required. In spite of its narrow therapeu-
tic window, which dictates careful dosing and monitoring,
quinine has been the drug of choice for the treatment of
severe malaria in Africa for over 30 years (and before that
was in use since the 17
th century). Exciting new results
from an African multi-centre trial now suggest that artesu-
nate should replace quinine as the first-line treatment [2].
In Kenya, however, changes are anticipated to take place
progressively over the coming years as practical issues,
such as making changes to national policy, procurement
and supply chain issues and re-training of health workers,
are tackled. In particular, the latter will demand a signifi-
cant injection of funds from the national malaria control
programme (Personal Communication, Dr Elizabeth Juma,
Head of Division of Malaria Control, Ministry of Public
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remain the default treatment.
Best approaches to treatment are often encompassed in
clinical practice guidelines (CPGs), tools to support health
workers to make evidence-informed decisions in the man-
agement of their patients. Ideally CPGs combine the best
available research gathered using standardized, robust,
systematic methods and contextual factors, such as cost,
feasibility, values, resources [3]. The World Health Organi-
zation (WHO), which is tasked with producing global clin-
ical guidance, particularly for developing countries, has
recently adopted one such transparent and systematic
approach to developing its CPGs. This process applies the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) tool to transparently assess the
quality of research evidence and develop recommenda-
tions [4]. The GRADE approach has rapidly become
widely used in full or in part, and is endorsed or used by
organizations including WHO, the UK’s National Institute
for Health and Clinical Excellence (NICE), the Scottish
Intercollegiate Guidelines Network (SIGN), and the
Cochrane Collaboration [5].
In March 2010, the WHO revised its malaria treatment
guidance as a framework for country-level policy makers
to adapt. For the first time, it incorporated the GRADE
approach [6]. In Kenya, the Division of Malaria Control
(DoMC) took the opportunity to revise its national guide-
lines for treatment of severe malaria in children, making
them consistent with the 2010 WHO Malaria treatment
guidelines (Table 1). In so doing, it changed Kenya’s
recommended quinine regimen from one that had been
disseminated and promoted for over 10 years. Specific
changes were an increase in the loading dose and mainte-
nance doses of quinine. This policy change coincided with
efforts by researchers, the Kenyan Ministry of Medical Ser-
vices and others to update CPGs for management of 12
key paediatric conditions, including malaria [7], an
approach also attempting to employ the GRADE tool [8].
However, as the 2010 WHO guidance did not employ the
GRADE approach to systematically appraise the evidence
available to inform the optimum use of quinine in African
children, a series of systematic reviews were conducted to
examine the quality of evidence available to help guide use
of quinine in this population using the GRADE approach.
This work demonstrates how treatment of severe malaria
has largely been neglected by the research community.
Further, it demonstrates how the GRADE tool helps make
this explicit, pointing to its potential value for highlighting
failures to invest in research on neglected diseases or
populations.
Methods
Key clinical questions to be tackled in a series of systema-
tic reviews that addressed the themes of effectiveness and
safety of quinine for the treatment of Kenyan children
with severe malaria were identified. These were:
1) Systematic review 1: Is there a value in administra-
tion of a loading dose of quinine in African children
with severe malaria?
2) Systematic review 2: Should Kenya change its recom-
mendation for treatment of severe malaria in children
under 5 of 15 mg/kg loading dose followed by 10 mg/kg
every 12 hours and replace it with the WHO recom-
mended regimen of 20 mg/kg loading dose followed by
10 mg/kg every 8 hours?
3) Systematic review 3: What are the pharmacoki-
netics and effectiveness of IV-administered quinine
compared to IM-administered quinine in African chil-
dren with severe malaria?
4) Systematic review 4: Is there a link between IV-
administered quinine and risk of hypoglycaemia in Afri-
can children with severe malaria?
The clinical questions were developed in a PICO (Popu-
lation, Intervention, Control/Comparator, Outcome) for-
mat and literature searches conducted in PubMed and the
Cochrane Library (up to September 2010) using MeSH
(Medical Subject Headings) search terms derived from
PubMed. Free text searches with no language or time lim-
itations were conducted. Additional searches were also
conducted in PubMed using the clinical queries filter tool.
Furthermore, bibliographies in the WHO guidelines and
abstracts of the 5th Multilateral Initiative on Malaria Pan-
African Malaria Conference (2-6 November 2009, Nairobi,
Kenya) were scanned. In a first round, identified manu-
script titles were independently screened by two investiga-
tors (NM, ME) using pre-defined inclusion/exclusion
Table 1 Summary of World Health Organization (2010) and Government of Kenya (2005 and 2010) clinical practice
guidelines for the management of children with severe malaria
Treatment for children aged <
5 years with a diagnosis of
severe malaria
GoK 2005
Basic Paediatric Protocols*
GoK 2010 Malaria Case
Management Guidelines
WHO 2010 Malaria Case
Management Guidelines
Pre-referral quinine loading dose 15 mg/kg IM injection 20 mg/kg IM injection 20 mg/kg IM injection
First-line treatment with quinine
dose
15 mg/kg loading dose then 10 mg/
kg every 12 hours by IV infusion or
divided IM injection
20 mg/kg loading dose then 10 mg/
kg every 8 hours by IV infusion or
divided IM injection
20 mg/kg loading dose then
10 mg/kg every 8 hours by
IV infusion or
divided IM injection
*Based on 1998 DoMC Malaria Treatment Guidelines.
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and full texts were read to select relevant studies to be
included in the systematic reviews. Data from included
studies were extracted into an in-house data extraction
tool. Quinine doses were uniformly presented in the salt
form as quinine sulphate. The GRADE tool was then used
to critically appraise the quality of each study and follow-
i n gt h a t ,t h eq u a l i t yo fa l la v a i l a b l ee v i d e n c ei n f o r m i n ga
particular question/outcome combination was categorized
based on GRADE guidelines (Table 3). Where no evidence
of heterogeneity was found, binary outcome data from
multiple studies were pooled in a random-effects model
using STATA 11 (STATA Corporation, College Station,
Texas, USA), and assessed for heterogeneity using the I-
Squared test.
Results
The number of studies identified in the literature search
for each question and then the number screened for
eligibility and final included studies in the respective
systematic reviews are presented in a series of flow dia-
grams (see Additional File 1).
Systematic review 1: Is there a value in administration of
a loading dose of quinine in African children with severe
malaria?
One Cochrane systematic review that was a meta-analysis
of four African randomized controlled trials was identi-
fied [9] (Table 4). Moderate to low quality evidence for
critical and important outcomes indicates that a quinine
loading dose of 19 to 21 mg/kg may make little or no dif-
ference to mortality, coma recovery time, convulsion fre-
quency, asexual parasitaemia at 24 and 48 hours,
neurological sequelae or adverse events including hypo-
gylcaemia, hypotension and arrhythmia. However, mod-
erate quality evidence indicates that a loading dose of 20
mg/kg quinine may reduce fever clearance time
[Weighted Mean Difference (WMD) 11.11, 95% Confi-
dence Interval (CI) 20.04 to 2.18; n = 68] and parasite
clearance time (WMD 7.44, 95% CI 13.24 to 1.64; n = 67)
as well as cause temporary hearing loss [Risk Ratio (RR)
3.14, 95% CI 1.05 to 9.38; n = 33] (see Additional File 2).
Systematic review 2: Should Kenya change its
recommendation for treatment of severe malaria in
children under 5 of 15 mg/kg loading dose followed by
10 mg/kg every 12 hours and replace it with the WHO
recommended regimen of 20 mg/kg loading dose
followed by 10 mg/kg every 8 hours?
There were no head to head comparisons or suitable indir-
ect comparison studies identified in the literature search.
Systematic review 3: What are the pharmacokinetics and
effectiveness of IV-administered quinine compared to IM-
administered quinine in African children with severe
malaria?
Seven studies in African children that evaluated quinine
administered with a loading dose by the IV or IM route
were identified [10-16]. In addition, three studies identi-
fied by a Cochrane review but on African children not
strictly having severe malar i aw e r ei n c l u d e d[ 1 7 ] .T h e s e
studies compared the effectiveness of quinine adminis-
tered with a loading dose by the rectal (IR) and the IV
route [18,19] and the IR and the IM route [20] (Table 5).
Systematic review 3a: What is the effectiveness of IV-
administered quinine compared to IM-administered
quinine in African children with severe malaria?
Two studies were identified that assessed the compara-
tive effectiveness of quinine route of administration by
t h eI Va n dI Mr o u t ew h e nal o a d i n gd o s eo f2 0m g / k g
was administered, with a maintenance dose of either 10
Table 2 Study selection inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
P. falciparum malaria Uncomplicated malaria
Randomized Controlled Trials (observational studies to be considered if no RCT evidence) IR administration
Children < 5 years old (older children and adult data to be considered if no studies in children)
Diagnosis of severe or complicated malaria, confirmed with microscopy or rapid diagnostic test or cerebral malaria
African setting
IM or IV administration
Table 3 Evidence quality and level of confidence in estimates using the GRADE approach
Evidence Quality Level of confidence in estimate
High Further research is very unlikely to change our confidence in the estimate of effect
Moderate Further research is likely to change our confidence in the estimate of effect, and may change the estimate
Low Further research is very likely to change the estimate of effect, and is likely to change the estimate
Very low The estimate of effect is very uncertain
Adapted from Guyatt et al 2008 [26]
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[13]. There was no difference between treatment groups
in all the reported outcomes of the individual studies
that were all appraised as low quality evidence - risk of
death, incidence of neurological sequelae, number of
convulsions, coma resolution time, parasite clearance
time, fever clearance time, number of hypoglycaemic
episodes or haemoglobin levels (see Additional File 3).
Further indirect evidence on mortality from 3 studies,
deemed to provide very low quality evidence (see Addi-
tional File 3), suggested there was no association
between risk of death (or any other outcome) and route
of administration from the studies that investigated IR
quinine vs IV quinine (n = 91 patients) in African chil-
dren [Odds Ratio (OR) 0.50, 95% CI 0.20 to 1.26; n =
186] [18,19] (Figure 1) or in one study that investigated
IR vs IM quinine (OR 0.15, 95% CI 0.01 to 3.28; n = 58)
[20]. Overall, therefore, available evidence is low or very
low quality to guide decisions on route of quinine
administration with the possibility that clinically impor-
tant risks or benefits exist, but are not recognized.
Systematic review 3b: What is the pharmacokinetics of
IV-administered quinine compared to IM-administered
quinine in African children with severe malaria?
Four identified studies evaluated the pharmacokinetics
of quinine when administered at a loading dose of 20
mg/kg, followed by a maintenance dose of 10 mg/kg
every 12 hours [10-12,16]. One study evaluated the
pharmacokinetics of quinine when administered at a
Table 4 Characteristics of studies that evaluated quinine loading dose (Systematic review 1)
Test quinine sulphate dose (IV) Comparator quinine sulphate dose (IV)
Study Age range Country Loading dose Maintenance dose Uniform dose
Assimadi 2002* (N = 72) 8 months to 15 years Benin 21 mg/kg 10.5 mg/kg every 12 hours 15.9 mg/kg every 12 hours
Fargier 1991* (N = 20) 15 years and above Cameroon 19 mg/kg 9.7 mg/kg every 8 hours 9.7 mg/kg every 8 hours
Pasvol 1991
# (N = 59) up to 12 years Kenya 20 mg/kg 10 mg/kg every 12 hours 5 to 10 mg/kg every 12 hours
Tombe 1992 (N = 33) 14 years and above Kenya 20 mg/kg 10 mg/kg every 8 hours 10 mg/kg every 8 hours
*Reported quinine doses converted from quinine base to quinine salt using salt conversion factor of 1.21
#N = 20 patients who received IM quinine were excluded from this analysis
Adapted from Lesi et al 2004 Cochrane systematic review [9]
Table 5 Characteristics of studies that evaluated effectiveness and pharmacokinetics of quinine by route of
administration (IV vs IM or indirect comparison of IR vs IV and IM vs IR) (Systematic review 3)
Study ID Age range Country IV Quinine Dose IM Quinine Dose
Waller 1990 (N = 21) 19 months to
8 years
Gambia N/A 20 mg/kg loading dose, then
10 mg/kg every 12 hours
Pasvol 1991
‡ (N = 59) up to 12 years Kenya 20 mg/kg loading dose, then 10 mg/kg every
12 hours
20 mg/kg loading dose, then
10 mg/kg every 12 hours
Krishna 1991 (N = 120) 1 to 10 years Ghana N/A 20 mg/kg loading dose, then
10 mg/kg every 12 hours
Schapira 1993 (N = 104) 6 months to
7 years
Mozambique 20 mg/kg loading dose, then 10 mg/kg every
8 hours
20 mg/kg loading dose, then
10 mg/kg every 8 hours
Winstanley 1993 (N = 22) 7 months to
6.8 years
Kenya 14 mg/kg loading dose, then 10 mg/kg every
12 hours
20 mg/kg loading dose, then
10 mg/kg every 12 hours
Winstanley 1994 (N = 9) 1 to 3 years Kenya 15 mg/kg loading dose, then 10 mg/kg every
12 hours
N/A
van Hensbroek 1996 (N = 16) 5 to 23
months
The Gambia 20 mg/kg loading dose, then 10 mg/kg every
12 hours
20 mg/kg loading dose, then
10 mg/kg every 12 hours
Study ID Age Country IR Quinine Dose IV Quinine Dose
Achan 2007
† (N = 110) 6 months to
5 years
Uganda 20 mg/kg base loading dose, then 10 mg/kg
every 8 hours, until oral treatment possible
8 mg/kg base every 8 hours, until
oral treatment possible
Bareness 1998
† (N = 77) 2 to 15 years Niger 11.8 mg/kg base loading dose, then 8.8 mg/kg
every 8 hours for 2 days, then oral treatment
with chloroquine
4.7 mg/kg base every 8 hours for
2 days, then oral treatment with
chloroquine
Study ID Age range Country IR Quinine Dose IM Quinine Dose
Bareness 2001
† (N = 58) 2 to 15 years Niger 17.9 mg/kg base loading dose, then 11.75 mg/
kg base every 12 hours
7.5 mg/kg base every 12 hours
† Quinimax formulation which consists of 96% quinine, 2.5% quinidine, 0.68% cinchonine, and 0.67% cinchonidine
‡N = 21 patients who received a lower dose of IV administered 10 mg/kg loading dose then 5 mg/kg every 12 hours were excluded from the IV vs IM
effectiveness analysis only.
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dose of 10 mg/kg every 8 hours [13]. Very low quality
evidence showed that there was no difference in the
reported pharmacokinetic parameters of quinine in the
individual studies - volume of distribution (Vd), maxi-
mum circulating concentration (Cmax), half-life (t1/2),
area under the curve (AUC) (Table 6).
Systematic review 4: Is there a link between IV-
administered quinine and risk of hypoglycaemia in
African children with severe malaria?
Six studies that evaluated the risk of hypoglycaemia in
the population and setting of interest to this review
were identified [2,21-25] (Table 7). Of these, five studies
[21-25] found no effect of IV quinine when given at a
slow infusion rate on the number of hypoglycaemic epi-
sodes or insulin levels in the children. An association
with hypoglycaemia was observed in children, however,
when quinine was administered at a high infusion rate.
Overall quality of evidence was rated as low or very low
to inform decisions on alternative quinine regimens.
Recently published high quality evidence, which evalu-
ated the effectiveness of quinine and the artemisinin
derivative artesunate in African children up to 15 years
of age, however, found 2.8% of patients treated with
quinine developed hypoglycaemic episodes, with artesu-
nate treatment associated with a significantly lower risk
(OR 0.63, 95% CI 0.43 to 0.91; n = 5,425) [2] (see Addi-
tional File 4).
Discussion
The WHO malaria treatment guidelines updated in
2010 have introduced the appraisal of studies using the
GRADE tool but only for newly acquired evidence since
the 2006 guidelines. Of relevance to severe malaria, this
encompassed only one topic, the comparison of safety
and effectiveness of quinine and artemisinin derivatives
in treating severe malaria, with reviews conducted
before the recently published large trial on artesunate
[2]. Other topics in the WHO 2010 guidance of (i) load-
ing dose of quinine (20 mg/kg) vs. no loading dose, (ii)
effectiveness of IM vs IM quinine, (iii) IM artemether vs
IV quinine and (iv) safety ande f f i c a c yo fp r e - r e f e r r a l
treatment with IR artesunate were reported as narrative
summaries of the evidence only, with no transparent
assessment or grading of recommendations. Although
the new data indicating the superiority of artesunate
compared with quinine (see Additional File 5) [2] will
change the landscape for guidelines, many African coun-
tries are likely to continue to rely on quinine therapy for
Achan 2007; IR n=56, IV n=54
Barennes 1998; IR n=39, IV n=37
Total: IR n=95, IV n=91
Figure 1 Meta analysis of comparison of effect of IR and IV administered quinine on mortality in African children.
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Page 5 of 9Table 6 Pharmacokinetic parameters of IV and IM administered quinine in African children (Systematic review 3b)
Study ID
(sample size)
Evidence
Quality
Route of
admn
Sample size
per arm
Quinine loading
dose
Quinine
maintenance dose
Infusion
time
Cmax
(mg/l)
tmax (h) t1/2 (h) Cl
(ml/min/kg)
Vd (l/kg) AUC
(mg/l/h)
Pasvol 1991 (N = 43) Low IV n = 21 10 mg/kg 5 mg/kg 2 h 9.7 ± 5.3 2.7 ± 1.3 8.9 ± 4.0 1.36 ± 0.58 0.87 ±
0.27
145 ± 61
Winstanley 1993
(N = 22)
Very
Low
IV n = 12 14 mg/kg 10 mg/kg bd 2 h 13.8 ±
3.1
- 16.4 ±
8.8
0.45 ± 0.13 0.45 ±
0.10
Winstanley 1994
(N = 9)
Very
Low
IV n = 9 15 mg/kg 10 mg/kg bd 2 h 17.9 ±
2.9
- 12.6 ±
3.1
0.81 ± 0.24 0.75 ±
0.11
Pasvol 1991 (N = 43) Low IV n = 18 20 mg/kg 10 mg/kg bd 2 h 15.3 ± 5.5 2.4 ± 1.5 12.5 ± 3.2 1.19 ± 0.29 1.22 ±
0.16
254 ± 86
van Hensbroek 1996
(N = 16)
Very
Low
IV n = 6 20 mg/kg 10 mg/kg bd 4 h 17.48 ±
2.43
- 13.16 ±
6.43
0.51 ± 0.16 1.04 ±
0.21
354 ± 143
Waller 1990 (N = 21) Very
Low
IM n = 21 20 mg/kg 10 mg/kg bd N/A 15.4 ±
4.5
3.23 ±
1.63
18.8 ±
8.0
0.89 ± 0.81 - 449 ±
243
Pasvol 1991 (N = 43) Low IM n = 20 20 mg/kg 10 mg/kg bd N/A 15.3 ±
7.6
2.4 ±
1.7
15.7 ±
8.2
1.12 ± 0.56 1.22 ±
0.32
332 ±
254
Winstanley 1993
(N = 22)
Very
Low
IM n = 10 20 mg/kg 10 mg/kg bd N/A 15.7 ±
3.1
1.6 ±
1.7
-- - -
van Hensbroek 1996
(N = 16)
Very
Low
IM n = 10 20 mg/kg 10 mg/kg bd N/A 16.36 ±
3.67
1.08 ±
0.37
15.31 ±
7.16
0.59 ± 0.25 1.32 ±
0.49
358 ±
164
Krishna 2001
(N = 120)
Very
Low
IM n = 120 20 mg/kg 10 mg/kg bd N/A - - 19.9 ±
4.4
0.05 - -
Legend:
Cmax (mg/l): Maximum circulating concentration
tmax (h): Time at maximum circulating concentration
t1/2 (h): Half-life
Cl (ml/min/kg): Clearance
Vd (l/kg): Volume of distribution
AUC (mg/l/h): Area under the curve.
M
u
s
i
l
a
e
t
a
l
.
M
a
l
a
r
i
a
J
o
u
r
n
a
l
2
0
1
1
,
1
0
:
2
0
1
h
t
t
p
:
/
/
w
w
w
.
m
a
l
a
r
i
a
j
o
u
r
n
a
l
.
c
o
m
/
c
o
n
t
e
n
t
/
1
0
/
1
/
2
0
1
P
a
g
e
6
o
f
9severe malaria in children for some years to come. Qui-
nine has well known, serious adverse effects and pre-
vious and current WHO recommendations (2010) have
not used systematic approaches when attempting to
appraise the evidence to guide dosing.
Despite more than 30 years of clinical use, only studies
of important (not critical) outcomes and only very low or
low quality evidence are available to inform most paedia-
tric quinine dosing decisions. Thus, there are no data
directly comparing the Kenyan regimen of the last 12
years and only limited data suggesting either the IV or IM
routes may be used, although IM quinine is mainly recom-
mended for pre-referral treatment due to the risks of
developing an IM injection abscess and other complica-
tions when incorrectly administered (Personal Communi-
cation, Dr Elizabeth Juma, Head of Division of Malaria
Control, Ministry of Public Health and Sanitation). Very
limited data also suggest that hypoglycaemia is more likely
with faster rates of administration. Only in the case of the
use of a loading dose is there moderate quality evidence to
guide recommendations, but only for what was considered
as non-critical outcomes. These included reduced fever
and parasite clearance time with loading doses, but also
higher risks of transient hearing loss with higher loading
doses [9].
This work thus indicates, historically, how the Kenyan
policy on quinine dosing that has been promoted nation-
wide for over 10 years, with considerable investments in
dissemination of guidelines and in-service training sup-
ported by global funds, was based predominantly on low
or very low quality evidence by today’s standards. The
available very low quality evidence does however suggest
similar pharmacokinetic parameters for the lower dose
Kenyan regimen as the currently recommended WHO
regimen. The fact that the 2010 WHO quinine dosing
regimens (that are unchanged) are also based on low
quality evidence, even for safety, does not provide an
obvious rationale for Kenya’s change to adopt the WHO
guidance. While it is considered entirely appropriate that
other factors are considered in making recommendations
based on evidence [3,26], this process is rarely transpar-
ent, as is the case with Kenya’sc h a n g eo fi t sq u i n i n e
regimen.
The emergent message from the series of systematic
reviews we conducted is the paucity of high quality evi-
dence that may inform the dose, route of administration
Table 7 Characteristics of studies that evaluated risk of hypoglyacemia with IV-infused quinine (Systematic review 4)
Study ID Evidence
quality
Age
range
Country IV Quinine Dose and diluent Infusion
time
Infusion
rate (ml/
kg/24 h)
Glucose
Threshold
(mmol/l)
Molyneux
1989
(N = 29)
Very low 2 to 9
years
Malawi 10 mg/kg in 5% glucose in half
strength Darrow’s solution
1 h 80 < 2.2
10 mg/kg in 5% glucose in half
strength Darrow’s solution
3 h 80 < 2.2
20 mg/kg in 5% glucose in half
strength Darrow’s solution
3 h 80 < 2.2
Okitolonda
1987
(N = 9)*
Very low 6 to 10
years
Zaïre 10 mg/kg in 30 ml saline
supplemented with 2.5%
glucose every 8 hours
1 h 105 < 2.8
Kawo 1991
(N = 97)
Very low Up to 7
years
Tanzania 10 mg/kg in 10 ml/kg of 5%
glucose every 8 hours
4 h Not
reported
< 2.2
Ogetii 2010
(N = 1237)
Low Up to
12 years
Kenya 15 mg/kg loading dose in 5%
dextrose then 10 mg/kg in 5%
dextrose every 12 hours
2 h Not
reported
< 3, < 2.8
and < 2.2
20 mg/kg loading dose in 5%
dextrose then 10 mg/kg in 5%
dextrose every 8 hours
4 h Not
reported
< 3, < 2.8
and < 2.2
Taylor 1988
(N = 95)
Very low 7
months
to 8
years
Malawi 20 mg/kg loading dose then 10
mg/kg every 8 hours
Loading dose
4h ,
then
maintenance
dose 2 to 8 h
80 < 2.2
Dondorp
2010
High Up to
15 years
Multi-centre trial in Mozambique, The
Gambia, Ghana, Kenya, Tanzania,
Nigeria, Uganda, Rwanda and
Democratic Republic of Congo
¥20 mg/kg loading dose in 5-10
ml/kg of 5% dextrose then 10
mg/kg in 5-10 ml/kg of 5%
dextrose every 8 hours
Loading dose
4h ,
then
maintenance
dose 2 to 8 h
Not
reported
Not
reported
*Data from N = 5 adults were excluded from this analysis
Ogetti 2010 = Retrospective review of case notes.
¥Quinine was administered by the IM and IV route.
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with severe malaria with quinine, notwithstanding that
quinine has been the standard treatment of severe
malaria for decades (Table 8). This contrasts starkly
with the evidence available to inform policy for children
with non-severe malaria. Here international efforts and
funding have supported over fifty randomized controlled
trials in recent years [27]. Despite huge investments to
tackle malaria over the last decade or more [28] it is
clear therefore that severe malaria in African children
has remained a neglected disease. In conducting these
systematic reviews we found the GRADE approach a
very useful tool for making the presence of only low
quality evidence explicit. This paper postulates that the
wider use of this or other similar approaches can help
build advocacy efforts for a greater research focus on
priority areas in paediatric therapeutics in African and
other low-income settings.
The recent findings of the large multicentre trial
demonstrating superiority of artesunate over quinine for
severe malaria in African children [2] provide a clear
argument for a change in approach on the continent.
These data demonstrate how poor the foundational
basis was for the use of quinine and should help argue
that the practical difficulties of introducing artesunate
should be overcome as soon as possible. Further, this
work supports that efforts to introduce explicit methods
of examining the evidence base for treatment of children
in low-income settings should be strongly supported.
Additional material
Additional file 1: Flow diagrams of the study selection process for
each of the systematic review questions. A series of flow diagrams
depicting the number of studies found in the literature search, the
number excluded during assessment and the final number included in
the systematic reviews.
Additional file 2: GRADE Table for studies included in systematic
review 1: Is there a value in administration of a loading dose of
quinine in African children with severe malaria?. Critical appraisal and
outcome data using the GRADE tool for Lesi 2004 Cochrane systematic
review.
Additional file 3: GRADE Tables for studies included in systematic
review 3a: What is the effectiveness of IV-administered quinine
compared to IM-administered quinine in African children with
severe malaria?. Critical appraisal and outcome data using the GRADE
tool for Schapira 1993, Pasvol 1991 (direct comparisons) and included
studies from the Eisenhut 2009 Cochrane systematic review - Achan
2007; Barennes 1998; Barennes 2001(indirect comparisons)
Additional file 4: GRADE Table for studies included in systematic
review 4: Is there a link between IV-administered quinine and risk
of hypoglycaemia in African children with severe malaria?. Critical
Table 8 Summary of quinine systematic reviews in the treatment of severe malaria in African children and
recommendations for evidence-informed clinical practice
Clinical Issue Recommendation Evidence
quality/strength
of
recommendation
Systematic review 1: Is there a value in
administration of a loading dose of quinine in
African children with severe malaria?
Quinine loading
dose [9]
Loading dose results in faster clearance of malaria
parasites from the blood stream and thus faster
clearance of fever and thus loading dose should be
administered, with monitoring and patient/care giver
support for episodes of partial hearing loss adverse
event
Moderate
Systematic review 3a: What is the effectiveness
of IV-administered quinine compared to IM-
administered quinine in African children with
severe malaria
Quinine route of
administration: IV
vs IM [11,13,18-20]
The clinical outcome of IV-administered quinine vs.
IM-administered quinine is equivocal in the
treatment of African children with severe malaria.
However, due to reported side effects with IM route,
such as risk of abscess and pain, the IV route is
preferred.
Low to very low
Systematic review 3b: What is the
pharmacokinetics of IV-administered quinine
compared to IM-administered quinine in African
children with severe malaria
Quinine paediatric
dose [10-12,14-16]
Pharmacokinetic profile of the old and new Kenyan
dosing regimen are similar
Low
Systematic review 4: Is there a link between IV-
administered quinine and risk of hypoglycaemia
in African children with severe malaria?
Quinine and risk of
hypoglycaemia
[2,21-25]
The risk of hypoglycaemia with quinine treatment in
African children with severe malaria may be
countered by administering the quinine at a low
infusion rate.
Glucose levels should be monitored due to
hypoglycaemic risk that occurs due to the disease
and/or quinine treatment, and should be treated
with glucose infusion
Low to high
AQUAMAT Findings Quinine vs
artemisinin
derivatives [2]
Artesunate is a superior treatment to quinine for
African children with severe malaria and should be
strongly considered for implementation as a first line
treatment, taking contextual factors such as cost-
effectiveness into account
High
Musila et al. Malaria Journal 2011, 10:201
http://www.malariajournal.com/content/10/1/201
Page 8 of 9appraisal and outcome data using the GRADE tool for Ogetti 2010 and
Dondorp 2010.
Additional file 5: GRADE Table for the African multi-centre trial
(AQUAMAT). Critical appraisal and mortality data using the GRADE tool
for Dondorp 2010 and Eltahir 2010.
Acknowledgements
NM is funded by ME’s Wellcome Trust Senior Fellowship (#076827).
NO is funded by a Wellcome Trust Strategic Award (#084538).
ME is funded by a Wellcome Trust Senior Fellowship (#076827).
NM acknowledges statistical advice from Ms Tansy Edwards and Dr John
Wagai.
The authors acknowledge useful discussions with Dr Andrew Nyandigisi and
Dr Dorothy Naisiae of the Division of Malaria Control, Ministry of Public
Health & Sanitation. This paper is published with the permission of the
director of KEMRI.
Author details
1Child and Newborn Health Group, Kenya Medical Research Institute-
Wellcome Trust Research Programme, PO Box 43640 - 00100, Nairobi, Kenya.
2Department of Paediatrics, John Radcliffe Hospital, University of Oxford,
Oxford, UK.
Authors’ contributions
ME conceived of the topics for the systematic reviews. NM developed the
methodology and conducted the reviews with assistance from NO. NM
drafted the manuscript and ME and NO contributed to it. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 January 2011 Accepted: 21 July 2011
Published: 21 July 2011
References
1. Rowe AK, Rowe SY, Snow RW, Korenromp EL, Schellenberg JR, Stein C,
Nahlen BL, Bryce J, Black RE, Steketee RW: The burden of malaria mortality
among African children in the year 2000. Int J Epidemiol 2006, 35:691-704.
2. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD,
Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T,
Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J,
Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A,
Mokuolu OA, Adedoyin OT, Johnson WBR, Tshefu AK, Onyamboko MA,
Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D,
Wills B, Oneko M, Peto TE, von Seidlein L, Day NPJ, White NJ, for the
AQUAMAT group: Artesunate versus quinine in the treatment of severe
falciparum malaria in African children (AQUAMAT): an open-label,
randomised trial. Lancet 2010, 376:1647-1657.
3. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A,
Schunemann HJ: Going from evidence to recommendations. BMJ 2008,
336:1049-1051.
4. Global Programme on Evidence for Health Policy, World Health
Organization Geneva, Switzerland: Guidelines for WHO Guidelines. 2003.
5. GRADE Working Group. [http://www.gradeworkinggroup.org/society/index.
htm].
6. World Health Organization: Guidelines for the Treatment of Malaria , Second
2010.
7. Ministry of Medical Services, Republic of Kenya: Basic Paedicatric Protocols
- Revised, September 2010 edition..
8. English M, Opiyo N: Getting to grips with GRADE - perspective from a
low-income setting. J Clin Epidemiol 2011, 64:708-710.
9. Lesi A, Meremikwu M: High first dose quinine regimen for treating severe
malaria. Cochrane Database Syst Rev 2004, 3:CD003341.
10. Waller D, Krishna S, Craddock C, Brewster D, Jammeh A, Kwiatkowski D,
Karbwang J, Molunto P, White NJ: The pharmacokinetic properties of
intramuscular quinine in Gambian children with severe falciparum
malaria. Trans R Soc Trop Med Hyg 1990, 84:488-491.
11. Pasvol G, Newton CR, Winstanley PA, Watkins WM, Peshu NM, Were JB,
Marsh K, Warrell DA: Quinine treatment of severe falciparum malaria in
African children: a randomized comparison of three regimens. Am J Trop
Med Hyg 1991, 45:702-713.
12. Krishna S, Nagaraja NV, Planche T, Agbenyega T, Bedo-Addo G, Ansong D,
Owusu-Ofori A, Shroads AL, Henderson G, Hutson A, Derendorf H,
Stacpoole PW: Population pharmacokinetics of intramuscular quinine in
children with severe malaria. Antimicrob Agents Chemother 2001,
45:1803-1809.
13. Schapira A, Solomon T, Julien M, Macome A, Parmar N, Ruas I, Simao F,
Streat E, Betschart B: Comparison of intramuscular and intravenous
quinine for the treatment of severe and complicated malaria in children.
Trans R Soc Trop Med Hyg 1993, 87:299-302.
14. Winstanley P, Newton C, Watkins W, Mberu E, Ward S, Warn P, Mwangi I,
Waruiru C, Pasvol G, Warrell D, Marsh K: Towards optimal regimens of
parenteral quinine for young African children with cerebral malaria: the
importance of unbound quinine concentration. Trans R Soc Trop Med Hyg
1993, 87:201-206.
15. Winstanley PA, Mberu EK, Watkins WM, Murphy SA, Lowe B, Marsh K:
Towards optimal regimens of parenteral quinine for young African
children with cerebral malaria: unbound quinine concentrations
following a simple loading dose regimen. Trans R Soc Trop Med Hyg 1994,
88:577-580.
16. van Hensbroek MB, Kwiatkowski D, van den Berg B, Hoek FJ, van Boxtel CJ,
Kager PA: Quinine pharmacokinetics in young children with severe
malaria. Am J Trop Med Hyg 1996, 54:237-242.
17. Eisenhut M, Omari AA: Intrarectal quinine versus intravenous or
intramuscular quinine for treating Plasmodium falciparum malaria.
Cochrane Database Syst Rev 2009, 21:CD004009.
18. Achan J, Byarugaba J, Barennes H, Tumwine JK: Rectal versus intravenous
quinine for the treatment of childhood cerebral malaria in Kampala,
Uganda: a randomized, double-blind clinical trial. Clin Infect Dis 2007,
45:1446-1452.
19. Barennes H, Munjakazi J, Verdier F, Clavier F, Pussard E: An open
randomized clinical study of intrarectal versus infused Quinimax for the
treatment of childhood cerebral malaria in Niger. Trans R Soc Trop Med
Hyg 1998, 92:437-440.
20. Barennes H, Kailou D, Pussard E, Munjakazi JM, Fernan M, Sherouat H,
Sanda A, Clavier F, Verdier F: [Intrarectal administration of quinine: an
early treatment for severe malaria in children?]. Sante 2001, 11:145-153.
21. Okitolonda W, Delacollette C, Malengreau M, Henquin JC: High incidence
of hypoglycaemia in African patients treated with intravenous quinine
for severe malaria. BMJ 1987, 295:716-718.
22. Taylor TE, Molyneux ME, Wirima JJ, Fletcher KA, Morris K: Blood glucose
levels in Malawian children before and during the administration of
intravenous quinine for severe falciparum malaria. N Engl J Med 1988,
319:1040-1047.
23. Molyneux ME, Taylor TE, Wirima JJ, Harper G: Effect of rate of infusion of
quinine on insulin and glucose responses in Malawian children with
falciparum malaria. BMJ 1989, 299:602-603.
24. Kawo NG, Msengi AE, Swai AB, Orskov H, Alberti KG, McLarty DG: The
metabolic effects of quinine in children with severe and complicated
Plasmodium falciparum malaria in Dar es Salaam. Trans R Soc Trop Med
Hyg 1991, 85:711-713.
25. Ogetii GN, Akech S, Jemutai J, Boga M, Kivaya E, Fegan G, Maitland K:
Hypoglycaemia in severe malaria, clinical associations and relationship
to quinine dosage. BMC Infect Dis 10:334.
26. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P,
Schunemann HJ: GRADE: an emerging consensus on rating quality of
evidence and strength of recommendations. BMJ 2008, 336:924-926.
27. Garner P, Gelband H, Graves P, Jones K, Maclehose H, Olliaro P: Systematic
reviews in malaria: global policies need global reviews. Infect Dis Clin
North Am 2009, 23:387-404.
28. Wellcome Trust UK: Principal Research Fellowship #079080..
doi:10.1186/1475-2875-10-201
Cite this article as: Musila et al.: Treatment of African children with
severe malaria - towards evidence-informed clinical practice using GRADE.
Malaria Journal 2011 10:201.
Musila et al. Malaria Journal 2011, 10:201
http://www.malariajournal.com/content/10/1/201
Page 9 of 9